The purpose of the study is to evaluate the drug levels, safety and tolerability of BMS-986368 in healthy Chinese participants
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
16
Specified dose on specified days
Specified dose of specified days
Maximum observed concentration (Cmax)
Time frame: Up to approximately Day 17
Time of maximum observed concentration (Tmax)
Time frame: Up to approximately Day 17
Area under the concentration-time curve (AUC)
Time frame: Up to approximately Day 17
Number of participants with adverse events (AEs)
Time frame: Up to approximately Day 44
Number of participants with serious adverse events (SAEs)
Time frame: Up to approximately Day 44
Number of participants with clinically significant vital sign measurements
Time frame: Up to approximately Day 17
Number of participants with clinically significant 12-lead electrocardiogram (ECG) examinations
Time frame: Up to approximately Day 17
Number of participants with clinically significant laboratory assessments
Time frame: Up to approximately Day 17
Number of participants with treatment emergent suicidal ideation and behavious assessed by Columbia Suicide Severity Rating Scale (C-SSRS)
Time frame: Up to approximately Day 17
Number of participants with changes with anxiety as assessed by Beck Anxiety Inventory (BAI)
Time frame: Up to approximately Day 17
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
First line of the email MUST contain NCT # and Site #.
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.